Beta Bionics (NASDAQ: BBNX) has recently received a number of price target changes and ratings updates:
- 9/23/2026 – Beta Bionics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $28.00 price target on the stock.
- 9/23/2026 – Beta Bionics was upgraded by Wells Fargo & Company to “strong-buy”.
- 9/19/2026 – Beta Bionics was upgraded by Wall Street Zen from “sell” to “hold”.
- 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $23.00 price target on the stock, up from $22.00.
- 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by UBS Group AG. They now have a $25.00 price target on the stock.
- 9/15/2026 – Beta Bionics had its price target raised by Bank of America Corporation from $18.00 to $20.00. They now have a “neutral” rating on the stock.
- 9/15/2026 – Beta Bionics had its price target raised by Robert W. Baird from $14.00 to $16.00. They now have a “neutral” rating on the stock.
- 9/14/2026 – Beta Bionics had its price target raised by Leerink Partners from $24.00 to $27.00. They now have an “outperform” rating on the stock.
- 8/21/2026 – Beta Bionics is now covered by William Blair. They set a “market perform” rating on the stock.
- 8/18/2026 – Beta Bionics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 7/28/2026 – Beta Bionics is now covered by UBS Group AG. They set a “buy” rating and a $22.00 price target on the stock.
Insider Buying and Selling
In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of Beta Bionics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 30,779 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the completion of the transaction, the insider owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 107,327 shares of company stock worth $2,070,421 over the last ninety days. Company insiders own 5.30% of the company’s stock.
The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.
Featured Stories
- Five stocks we like better than Beta Bionics
- 3 Energy ETFs Built for Oil’s New $100-Plus Reality
- Can Marvell Keep Up in the Custom AI Chip Race?
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
Receive News & Ratings for Beta Bionics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
